Late responses to adenoviral-mediated transfer of the aquaporin-1 gene for radiation-induced salivary hypofunction
I Alevizos, C Zheng, A P Cotrim, S Liu, L McCullagh, M E Billings, C M Goldsmith, M Tandon, E J Helmerhorst, M A Catalán, S J Danielides, P Perez, N P Nikolov, J A Chiorini, J E Melvin, F G Oppenheim, G G Illei, B J Baum, I Alevizos, C Zheng, A P Cotrim, S Liu, L McCullagh, M E Billings, C M Goldsmith, M Tandon, E J Helmerhorst, M A Catalán, S J Danielides, P Perez, N P Nikolov, J A Chiorini, J E Melvin, F G Oppenheim, G G Illei, B J Baum
Abstract
We evaluated late effects of AdhAQP1 administration in five subjects in a clinical trial for radiation-induced salivary hypofunction (http://www.clinicaltrials.gov/ct/show/NCT00372320?order=). All were identified as initially responding to human aquaporin-1 (hAQP1) gene transfer. They were followed for 3-4 years after AdhAQP1 delivery to one parotid gland. At intervals we examined salivary flow, xerostomic symptoms, saliva composition, vector presence and efficacy in the targeted gland, clinical laboratory data and adverse events. All displayed marked increases (71-500% above baseline) in parotid flow 3-4.7 years after treatment, with improved symptoms for ~2-3 years. There were some changes in [Na+] and [Cl-] consistent with elevated salivary flow, but no uniform changes in secretion of key parotid proteins. There were no clinically significant adverse events, nor consistent negative changes in laboratory parameters. One subject underwent a core needle biopsy of the targeted parotid gland 3.1 years post treatment and displayed evidence of hAQP1 protein in acinar, but not duct, cell membranes. All subjects responding to hAQP1 gene transfer initially had benefits for much longer times. First-generation adenoviral vectors typically yield transit effects, but these data show beneficial effects can continue years after parotid gland delivery.
Figures
References
- Jensen SB, Pedersen AM, Vissink A, Andersen E, Brown CG, Davies AN, et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer. 2010;18:1039–1060.
- Vissink A, van Luijk P, Langendijk JA, Coppes RP. Current ideas to reduce or salvage radiation damage to salivary glands. Oral Dis. 2015;21:e1–e10.
- Schwartz-Arad D, Arber L, Arber N, Zajicek G, Michaeli Y. The rat parotid gland – a renewing cell population. J Anat. 1988;161:143–151.
- Redman RS. Proliferative activity by cell type in the developing rat parotid gland. Anat Rec. 1995;241:529–540.
- Van Luijk P, Pringle S, Deasy JO, Moiseenko VV, Faber H, Hovan A, et al. Sparing the region of the salivary gland containing stem cells preserves saliva production after radiotherapy for head and neck cancer. Sci Transl Med. 2015;7:305ra147. doi:1126scitranslmed.aac4441.
- Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys. 1995;31:1341–1346.
- Mastrangeli A, O’Connell B, Aladib W, Fox PC, Baum BJ, Crystal RG. Direct in vivo adenovirus-mediated gene transfer to salivary glands. Am J Physiol. 1994;266:G1146–G1155.
- Delporte C, O’Connell BC, He X, Lancaster HE, O’Connell AC, Agre P, et al. Increased fluid secretion after adenoviral-medicated transfer of the aquaporin-1 cDNA to irradiated rat salivary glands. Proc Natl Acad Sci (USA) 1997;94:3268–3273.
- Vitolo JM, Baum BJ. The use of gene transfer for the protection and repair of salivary glands. Oral Dis. 2002;8:183–191.
- Shan Z, Li J, Zheng C, Liu X, Fan Z, Zhang C, et al. Increased fluid secretion after adenoviral-mediated transfer of the human aquaporin-1 cDNA to irradiated miniature pig parotid glands. Mol Ther. 2005;11:444–45.
- Preston GM, Agre P. Isolation of the cDNA for the erythrocyte integral membrane protein of 28 kilodaltons: member of an ancient channel family. Proc Natl Acad Sci (USA) 1991;88:11110–11114.
- Baum BJ, Alevizos I, Zheng C, Cotrim AP, Liu S, McCullagh L, et al. Early responses to adenoviral-mediated transfer of the aquaporin-1 cDNA for radiation-induced salivary hypofunction. Proc Natl Acad Sci (USA) 2012;109:19403–19407.
- Wang Z, Zourelias L, Wu C, Edwards PC, Trombetta M, Passineau MJ. Ultrasound-assisted nonviral gene transfer of AQP1 to the irradiated minipig parotid gland restores fluid secretion. Gene Ther. 2015;22:739–749.
- Diggle PJ, Heagerty P, Liang K-Y, Zeger SL. Oxford Statistical Science Series. Oxford University Press; Oxford, UK: 2002. Analysis of Longitudinal Data. ISBN978-0-19-852484-7.
- Pai S, Ghezzi EM, Ship JA. Development of a Visual Analogue Scale questionnaire of subjective assessment of salivary dysfunction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;91:311–316.
- Alevizos I, Zheng C, Cotrim AP, Goldsmith CM, McCullagh L, Berkowitz T, et al. Immune reactivity after adenoviral-mediated cDNA transfer to human parotid glands. Oral Dis. doi: 10.1111/odi.12614, in press.
- Gresz V, Kwon TH, Hurley PT, Varga G, Zelles T, Nielsen S, et al. Identification and localization of aquaporin water channels in human salivary glands. Am J Physiol. 2001;281:G247–G254.
- Harvey BG, Hackett NR, El-Sawy T, Rosengart TK, Hirschowitz EA, Lieberman MD, et al. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J Virol. 1999;73:6729–6742.
- Harvey BG, Hackett NR, Ely S, Crystal RG. Host responses and persistence of vector genome following intrabronchial administration of an E1 (-) E3(-) adenovirus gene transfer vector to normal individuals. Mol Ther. 2001;3:206–215.
- Muona K, Makinen K, Hedman M, Manninen H, Yia-Herttuala S. 10-year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb. Gene Ther. 2012;19:392–395.
- Hendrikx R, Stichling N, Koelen J, Kuryk L, Lipiec A, Greber UF. Innate immunity to adenovirus. Hum Gene Ther. 2014;25:265–284.
- Seregen SS, Appledorn DM, McBride AJ, Schuldt NJ, Aldhamen YA, Voss T, et al. Transient pretreatment with glucocorticoid ablates inate toxicity of systemically delivered adenoviral vectors without reducing efficacy. Mol Ther. 2009;17:685–696.
- Laakkonen JP, Yia-Herttuala S. Recent advances in cardiovascular gene therapy and vascular biology. Hum Gene Ther. 2015;26:518–524.
- Wang S, Baum BJ, Yamano S, Mankani MH, Sun D, Jonsson M, et al. Adenoviral-mediated gene transfer to mouse salivary glands. J Dent Res. 2000;79:701–708.
- Kagami H, Atkinson JC, Michalek SM, Handelman B, Yu S, Baum BJ, et al. Repetitive adenovirus administration to the parotid gland: role of immunological barriers and induction of oral tolerance. Hum Gene Ther. 1998;10:305–313.
- Li J, Zheng C, Zhang X, Liu X, Zhang C, Goldsmith CM, et al. Development of a large animal model for gene transfer to salivary glands in vivo. J Gene Med. 2004;6:55–63.
- Voutetakis A, Zheng C, Metzger M, Cotrim AP, Donahue RE, Dunbar CE, et al. Sorting of transgenic secretory proteins in rhesus macaque parotid glands after adenovirus-mediated gene transfer. Hum Gene Ther. 2008;19:1401–1405.
- Zheng C, Vitolo JM, Zhang W, Mineshiba F, Cjiorini JA, Baum BJ. Extended transgene expression from a nonintegrating adenoviral vector containing retroviral elements. Mol Ther. 2008;16:1089–1097.
- Zheng C, Baum BJ, Liu X, Goldsmith CM, Perez P, Jang SI, et al. Persistence of hAQP1 expression in human salivary gland cells following AdhAQP1 transduction is associated with a lack of methylation of the hCMV promoter. Gene Ther. 2015;22:758–766.
- Thaysen JH, Thorn NA, Schwartz IL. Excretion of sodium, potassium, chloride and carbon dioxide in human parotid saliva. Am J Physiol. 1954;178:155–159.
- Baum BJ. Principles of saliva secretion. Ann NY Acad Sci. 1993;694:17–23.
- Teos LY, Zheng C-Y, Liu X, Swaim WD, Goldsmith CM, Cotrim AP, et al. Adenovirus-mediated hAQP1 expression in irradiated mouse salivary glands causes recovery of saliva secretion by enhancing acinar cell volume decrease. Gene Ther. 2016;23:572–579.
- Atkinson JC, Yeh C-K, Bermudez D, Fox PC, Baum BJ. Longitudinal evaluation of major salivary gland function in HIV-1 infected patients. J Oral Pathol Med. 1989;18:469–470.
- Percival RS, Challacombe SJ, Marsh PD. Flow rates of resting whole and stimulated parotid saliva in relation to age and gender. J Dent Res. 1994;73:1416–1420.
- Ghezzi EM, Lange LA, Ship JA. Determination of variation of stimulated salivary flow rates. J Dent Res. 2000;79:1874–1878.
- Sprangers MC, Lakhai W, Koudstaal W, Verhoeven M, Koel BF, Vogels R, et al. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol. 2003;41:5046–52.
- Zheng C, Nikolov NP, Alevizos I, Cotrim AP, Liu S, McCullagh L, et al. Transient detection of E1-containing adenovirus in saliva after the delivery of a first-generation adenoviral vector to human parotid gland. J Gene Med. 2010;12:3–10.
- Nakamoto T, Brown DA, Catalán M, Gonzalez-Begne M, Romanenko VG, Melvin JE. J Biol Chem. 2009;284:4815–4822.
- Campese M, Sun X, Bosch JA, Oppenheim FG, Helmerhorst EJ. Concentration and fate of histatins and acidic proline-rich proteins in the oral environment. Arch Oral Biol. 2009;54:345–353.
Source: PubMed